NOTIFICATION

The following notification is being circulated in accordance with Article 10.6

|  |  |
| --- | --- |
| **1.** | **Notifying Member:** BRAZIL**If applicable, name of local government involved (Article 3.2 and 7.2):**  |
| **2.** | **Agency responsible:** Brazilian Health Regulatory Agency (ANVISA)**Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:** National Institute of Metrology, Quality and Technology (INMETRO)Telephone: +(55) 21 2145.3817Telefax: +(55) 21 2563.5637Email: barreirastecnicas@inmetro.gov.brWeb-site: www.inmetro.gov.br/barreirastecnicas |
| **3.** | **Notified under Article 2.9.2 [****X],** **2.10.1 [****],** **5.6.2 [****],** **5.7.1 [****], 3.2 [****], 7.2 [****],** **other****:**  |
| **4.** | **Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable):** Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale. (HS code(s): 3003); Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. (HS code(s): 3004) |
| **5.** | **Title, number of pages and language(s) of the notified document:** Resolution - RDC number 721, 01 July 2022; (55 page(s), in Portuguese) |
| **6.** | **Description of content:** This Resolution contains provisions on marketing authorization, renewal of marketing authorization, post-marketing authorization changes and notification of industrialized dynamized drugs. The current editions of the following pharmacopoeias and compendia should be used as a reference for production methods and quality control of drugs, excipients, active ingredients and industrialized dynamized drugs:I - Brazilian Homeopathic Pharmacopoeia;II - German Homeopathic Pharmacopoeia (GHP/HAB);III - American Homeopathic Pharmacopoeia (HPUS);IV - British Homeopathic Pharmacopoeia (BHP);V - Mexican Homeopathic Pharmacopoeia;VI - Indian Homeopathic Pharmacopoeia;VII - European Pharmacopoeia (Ph. EUR.);VIII - French Pharmacopoeia (PhFr); orIX - Anthroposophical Pharmaceutical Code (APC). |
| **7.** | **Objective and rationale, including the nature of urgent problems where applicable:** This Resolution aims to establish minimum requirements for market registration, market registration renewal, post-market registration changes and notification of industrialized dynamized drugs.; Protection of human health or safety |
| **8.** | **Relevant documents:** - |
| **9.** | **Proposed date of adoption:** 1 August 2022**Proposed date of entry into force:** 1 August 2022 |
| **10.** | **Final date for comments:** Not Applicable |
| **11.** | **Texts available from: National enquiry point [****]** **or address, telephone and fax numbers and email and website addresses, if available, of other body:** Brazilian Health Regulatory Agency (Anvisa)SIA, Trecho 5, Área Especial 57Brasília – DF / BrazilCEP: 71.205-050Phone.: +(55) 61 3462.5402Website: www.anvisa.gov.brThe final text is available only in Portuguese and can be downloaded at:<http://antigo.anvisa.gov.br/documents/10181/2718376/RDC_721_2022_.pdf/e0a6da8f-aeee-457e-9457-aca3be932e0d> |